12. Spector affects -1 of 3500 to 5000 newborn males (1). Both DMD and the milder allelic Becker muscular dystrophy (BMI)) result from mutations in the dystrophin gene. The 14-kb coding sequence of the dystrophin gene has been cloned (2). Use of cDNA probes has shown that molecular deletions account for -65% of the mutations in DM1) and . Carrier detection in the deletion cases involves assessing gene dosage by quantitative Southern-blot analysis, whereby one determines whether the female at risk exhibits no reduction (noncarrier status) or 50% reduction (carrier status) in hybridization intensity in those bands that are deleted in the affected male (7). The dosage determinations permit direct analysis for carrier status and eliminate the inherent problems of the restriction-fragment-lengthpolymorphism technique (e.g., recombinations, noninformative meioses, unavailability of family members, and sporadic mutations). To further increase the accuracy of the dosage analysis, we quantify the autoradiographic bands by scanning with a densitometer (8) .
ization and low background. To obtain this high quality, we have found that -20% of the Southern blots have to be repeated, increasing time and labor. Rather than directly comparing single bands, band ratios are calculated as a means of decreasing the error caused by differences in the amount of DNA in each lane. The normal control ratio is established by comparing in an unaffected female a band lacking in the patient against a band present in the patient (which serves as an internal control). A ratio in a female (at risk) that is approximately half the control ratio indicates that she has a single copy of the band deleted in the patient and therefore is a carrier.
Depending on the extent of the deletion, the restriction fragments involved in the deletion, and the specific cDNA probe that identifies the deletion, one may be extremely limited as to what bands can be used in the control ratio. We have found that bands >10 kb and <0.5 kb typically result in weaker intensities and are not always adequate for scanning purposes. Mao and Cremer (9) recently stated that, for deletions in the center of the gene (cDNA 8 hybridizations), they prefer to make a statement regarding carrier status only if at least one of the strong hybridizing fragments (7, 3.8, 3.7, or 3.1 kb) is deleted in the patient. Furthermore, the difference between one or two copies is relatively easy to detect but differences between two and three copies, or sometimes three or four copies, in the case of a duplication or comigrating bands can be very difficult. Finally, because of the extent of a deletion in an affected individual, no hybridizing bands may be detected with a cDNA probe, so that comparison of hybridization bands within a lane is not possible in these cases.
Given these limitations, we investigated the possibility of using quantitative polymerase chain reaction (PCR) to determine dosage (10) . After identifying the deletion in the affected individual, specific DMD exons of the female relative are amplified (11) , hybridized with allele-specific oligonucleotides (ASOs) and used in the dosage ratio calculation. The purpose of this paper is to evaluate the technique and illustrate its application through an actual case study.
Materials and Methods
Blood specimens were collected from patients with DM1) or BMD at the Ohio State University Hospital. Diagnosis was based on clinical symptomology, above-normal activities of CK, and muscle histology. Genomic DNA was extracted by a salting-out procedure (12) The PCR products were transferred to a nylon membrane (Zetabind; CUNO, Inc., Meriden, CT) by Southern blotting with a solution of 0.5 mol of NaOH and 0.6 mol of NaC1 per liter (13, 14) . The filter was prehybridized at 37#{176}C in the following mixture: 5x SSC (lx SSC = NaC1, 0. 15 Table 1 . The degree of hybridization was assessed by using a CS-9000 scanning densitometer (Shimadzu Corp., Kyoto, Japan). The area under the peak represents the intensity of each hybridization band.
Results

Analytical Pertormance
Range: Because the extension product of each primer serves as a template for the other primer, each cycle essentially doubles the amount of the DNA product produced in the previous PCR cycle. This results in the exponential accumulation of the specific fragment, up to several millionfold in a few hours. To obtain quantitative results, one must measure the PCR products during the exponential phase of the amplification process.This occurs when the primers, nucleotides, and Taq polymerase are in a large excess over that of the template concentration. In our experience, after the number of cycles (25-30) adequate to make visible the PCR products on an ethidium-bromidestained gel is complete, the PCR reaction is no longer in the quantitative range. Therefore, one must determine the appropriate number of PCR cycles for each primer set.
To do this, we amplified exons 8 and 19 from a series of identical samples, containing 1 tg of DNA, from eight to 16 cycles. We removed 20-pL aliquots of amplified DNA samples from different cycle numbers, ran these on an agarose gel, Southern blotted, hybridized with the corresponding ASOs, and scanned with the densitometer. The autoradiograph and a graph displaying densitometric band intensity vs the cycle number are shown Figure 1 . Linearity was maintained through 15 cycles but the curve started to plateau slightly at cycle 16. The 8/19 exon ratio remained constant over the entire range of cycles (CV 6.2%). Good We amplified a dilution series for several of the DMD exons to establish the relation between input target DNA and hybridization intensity. Densitometric scans showed a linear relation between input DNA (which ranged from 0.5 to 3.0 jig) and hybridization signal for several dystrophin exons. However, the signal produced is a function not only of the amount of DNA, but also of the exposure time and the specific activity of the ASO. Because these factors result in proportional changes in the band intensities, quantification of the ratios has been shown to be maintained over a wide range of exposure times (depending on the age of the isotope). The results for exon 45 are shown in Figure 2 . We determined that the products resulting from the PCR were proportional to the input target DNA over a range of input concentrations of target sequence. This is important, given the variations in the starting DNA concentrations that may occur between patients and controls.
Precision:
Within-run precision of the dosage ratio was calculated from nine PCR amplifications and ASO hybridizations of DMD exons 8 and 48 (Figure 3) . The autoradiogram was scanned and we determined the CV to be 15%. Calculated CVs from other dosage ratios have ranged from 5% to 20%. We have observed similar values for precision when scanning from Southern blots. Although the results show some imprecision in the PCR dosage ratios, the precision is adequate for distinguishing hemizygous (half band intensity) from the homozygous samples (normal band intensity). We have not observed overlap between the ratios for normal controls and DMD carriers. However, as a means of reducing any possible overlap and ensuring the accuracy of the dosage analysis, we commonly amplify several appropriate exons and use multiple ratios as an internal confirmation of the results. This is a distinct advantage of performing dosage from PCR hybridizations because, given the extent of the deletion and the specific cDNA hybridization, one often cannot use multiple ratios when performing dosage from Southern blots.
Case Study
Southern-blot analysis of DNA from a DMD patient showed a large molecular deletion for exons 10-41 of the DMD gene. Figure 4 shows a photograph of an ethidiumbromide-stained gel after amplification of exon 8 and 19 in the patient, his mother, and an unaffected control. Although there was no family history of DMD, the mother had above-normal concentrations of creatine kinase (EC 2.7.3.2) on three separate occasions, strongly suggesting positive carrier status. As shown, exon 19 is clearly deleted for the child, but it is difficult to see whether the mother is also carrying the deletion. To accumulate visible PCR products, it is usually necessary to amplify for at least 20 cycles. However, because the PCR reaction plateaus at high cycle numbers, we have not been able to definitively determine carrier status from an ethidiumbromide-stained gel. Therefore, we amplified exons 8 and 19 in the mother, proband, and a normal control for 12 cycles, hybridized them with the corresponding ASOs, and scanned the autoradiograms ( Figure   5 ). The 19/8 exon ratio in the mother is 0.3, approximately half the normal control ratio (0.8). Therefore, we conclude that the mother is carrying the deletion and is positive for DMD carrier status, thus supporting her above-normal creatine kinase results. We have found the quantitative PCR technique to be extremely reliable, because all family carrier determinations (10 families during this study) have subsequently been confirmed by Southern dosage analysis. We elected to show a case in which the mother was positive for DMD carrier status; however, the results of Southern blots and quantitative PCRs have been in agreement for noncarriera also.
Discussion
There being at present no cures for DMD or BMD, the accurate identification of carriers is of the utmost impor- nonaffected control em analysis. Furthermore, this assay requires lessDNA, can be performed more rapidly than Southern analysis, and is both cost-and labor-effective. However, for reliable quantification of the amount of DNA, the range of concentrations of template and the number of amplification cycles must be determined such that they stay within the exponential phase of the PCR. Therefore, we had to define the range of concentrations that gave an exponential amplification over a defined range of cycle numbers. The conditions were relatively liberal, and the PCR reaction could be accurately quantified over a range of cycle numbers and starting DNA template concentrations. Moreover, as demonstrated, the assay could clearly differentiate the carrier state in a DMD carrier mother.
Deletions have been shown to account for -65% of the DMD and BMD cases. Because most of the deletions (-98%) can be identified with the multiplex PCR (15) , one can now also perform carrier studies by using PCR amplification. Upon determining the extent of the deletion in affected subjects, one selects the specific exons (an exon that is deleted and an exon that is present in those affected) and performs amplification and ASO hybridizations in the females at risk and in controls. Although we have utilized only four ASOs in this report, the sequence of the eDNA has been published (16) and one can use any number of ASOs derived from exon sequences. We therefore recommend using multiple ratios as an internal control for carrier studies. We have found the method to be reliable and are currently using it for all carrier studies for which the affected male has a deletion.
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